508 related articles for article (PubMed ID: 10477568)
1. Beta-glucan, a "specific" biologic response modifier that uses antibodies to target tumors for cytotoxic recognition by leukocyte complement receptor type 3 (CD11b/CD18).
Yan J; Vetvicka V; Xia Y; Coxon A; Carroll MC; Mayadas TN; Ross GD
J Immunol; 1999 Sep; 163(6):3045-52. PubMed ID: 10477568
[TBL] [Abstract][Full Text] [Related]
2. The beta-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells.
Xia Y; Vetvicka V; Yan J; Hanikýrová M; Mayadas T; Ross GD
J Immunol; 1999 Feb; 162(4):2281-90. PubMed ID: 9973505
[TBL] [Abstract][Full Text] [Related]
3. Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells.
Hong F; Hansen RD; Yan J; Allendorf DJ; Baran JT; Ostroff GR; Ross GD
Cancer Res; 2003 Dec; 63(24):9023-31. PubMed ID: 14695221
[TBL] [Abstract][Full Text] [Related]
4. Targeting of natural killer cells to mammary carcinoma via naturally occurring tumor cell-bound iC3b and beta-glucan-primed CR3 (CD11b/CD18).
Vetvicka V; Thornton BP; Wieman TJ; Ross GD
J Immunol; 1997 Jul; 159(2):599-605. PubMed ID: 9218574
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the sugar specificity and molecular location of the beta-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18).
Thornton BP; Vĕtvicka V; Pitman M; Goldman RC; Ross GD
J Immunol; 1996 Feb; 156(3):1235-46. PubMed ID: 8558003
[TBL] [Abstract][Full Text] [Related]
6. Critical role of Kupffer cell CR3 (CD11b/CD18) in the clearance of IgM-opsonized erythrocytes or soluble beta-glucan.
Yan J; Vetvicka V; Xia Y; Hanikýrová M; Mayadas TN; Ross GD
Immunopharmacology; 2000 Jan; 46(1):39-54. PubMed ID: 10665778
[TBL] [Abstract][Full Text] [Related]
7. Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells.
Vetvicka V; Thornton BP; Ross GD
J Clin Invest; 1996 Jul; 98(1):50-61. PubMed ID: 8690804
[TBL] [Abstract][Full Text] [Related]
8. Generation of recombinant fragments of CD11b expressing the functional beta-glucan-binding lectin site of CR3 (CD11b/CD18).
Xia Y; Ross GD
J Immunol; 1999 Jun; 162(12):7285-93. PubMed ID: 10358177
[TBL] [Abstract][Full Text] [Related]
9. CD11b/CD18 integrin and a beta-glucan receptor act in concert to induce the synthesis of platelet-activating factor by monocytes.
Elstad MR; Parker CJ; Cowley FS; Wilcox LA; McIntyre TM; Prescott SM; Zimmerman GA
J Immunol; 1994 Jan; 152(1):220-30. PubMed ID: 7902855
[TBL] [Abstract][Full Text] [Related]
10. Requirement of leukocytic cell adhesion molecules (CD11a-c/CD18) in the enhanced NK lysis of iC3b-opsonized targets.
Ramos OF; Patarroyo M; Yefenof E; Klein E
J Immunol; 1989 Jun; 142(11):4100-4. PubMed ID: 2565929
[TBL] [Abstract][Full Text] [Related]
11. Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models.
Hong F; Yan J; Baran JT; Allendorf DJ; Hansen RD; Ostroff GR; Xing PX; Cheung NK; Ross GD
J Immunol; 2004 Jul; 173(2):797-806. PubMed ID: 15240666
[TBL] [Abstract][Full Text] [Related]
12. Staurosporine inhibits neutrophil phagocytosis but not iC3b binding mediated by CR3 (CD11b/CD18).
Roubey RA; Ross GD; Merrill JT; Walton F; Reed W; Winchester RJ; Buyon JP
J Immunol; 1991 May; 146(10):3557-62. PubMed ID: 1673986
[TBL] [Abstract][Full Text] [Related]
13. Regulation of the adhesion versus cytotoxic functions of the Mac-1/CR3/alphaMbeta2-integrin glycoprotein.
Ross GD
Crit Rev Immunol; 2000; 20(3):197-222. PubMed ID: 10968371
[TBL] [Abstract][Full Text] [Related]
14. Oral (1-->3),(1-->4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma.
Cheung NK; Modak S
Clin Cancer Res; 2002 May; 8(5):1217-23. PubMed ID: 12006541
[TBL] [Abstract][Full Text] [Related]
15. Beta-glucan enhances complement-mediated hematopoietic recovery after bone marrow injury.
Cramer DE; Allendorf DJ; Baran JT; Hansen R; Marroquin J; Li B; Ratajczak J; Ratajczak MZ; Yan J
Blood; 2006 Jan; 107(2):835-40. PubMed ID: 16179370
[TBL] [Abstract][Full Text] [Related]
16. The function of human NK cells is enhanced by beta-glucan, a ligand of CR3 (CD11b/CD18).
Di Renzo L; Yefenof E; Klein E
Eur J Immunol; 1991 Jul; 21(7):1755-8. PubMed ID: 2060581
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic intervention with complement and beta-glucan in cancer.
Ross GD; Vetvicka V; Yan J; Xia Y; Vetvicková J
Immunopharmacology; 1999 May; 42(1-3):61-74. PubMed ID: 10408367
[TBL] [Abstract][Full Text] [Related]
18. Potentiation of NK cytotoxicity by antibody-C3b/iC3b heteroconjugates.
Yefenof E; Benizri R; Reiter Y; Klein E; Fishelson Z
J Immunol; 1990 Feb; 144(4):1538-43. PubMed ID: 2303717
[TBL] [Abstract][Full Text] [Related]
19. Regulation of CR3 (CD11b/CD18)-dependent natural killer (NK) cell cytotoxicity by tumour target cell MHC class I molecules.
Vĕtvicka V; Hanikýrová M; Vĕtvicková J; Ross GD
Clin Exp Immunol; 1999 Feb; 115(2):229-35. PubMed ID: 9933447
[TBL] [Abstract][Full Text] [Related]
20. Cross-linking tumor cells with effector cells via CD55 with a bispecific mAb induces beta-glucan-dependent CR3-dependent cellular cytotoxicity.
Gelderman KA; Lam S; Sier CF; Gorter A
Eur J Immunol; 2006 Apr; 36(4):977-84. PubMed ID: 16525993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
